




Analysis of DNA alterations and RNA expression levels to guide treatment selection

Sequencing and analysis

Co-isolate DNA and RNA

FIG. 1




FIG. 2







FIG. 3



FIGS. 4A-4D



FIGS 5A-5D



FIGS. 6A-6C




FIG. 7

StrataEXP™ Reported Biomarkers†

Therapeutic RNA Expression Targets		
Gene Name	Associated Therapies	Example Tumor Type Response Rates
ERBB2 (HER2)	Heruzma (trastuzumab-pkrb); Perjeta (pertuzumab); Herceptin (trastuzumab); Kadcyla (ado-trastuzumab emtansine)	Her2+ Breast (50.0% ORR)
CD274 (PD-L1)	Keytruda (pembrolizumab); Opdivo (nivolumab); Libtayo (cemiplimab-rwlg); Tecentrig (atezolizumab)	PD-L1+ NSCLC (45% ORR)
AR (Androgen receptor)	Zytiga (abiraterone acetate); Xtandi (enzalutamide)	Prostate (33% ORR)
FVRL4 (Nectin-4)	Padcev (fenfortumab vedotin)	Bladder (44% ORR)
TACSTD2 (TROP2)	Trodely (sacituzumab govitecan)	TNBC (32% ORR); Bladder (20% ORR)
SLC39A6 (LIV-1)*	SGN-LIV1A (adiratuzumab vedotin)	TNBC (32% ORR)
SLC34A2 (NaPi2b)*	XMT-1536	Ovarian (24% ORR)
FOLR1 (Folate receptor)*	Miveximab soravudansine; STRO-002	Ovarian (22% ORR); (32% ORR)
FOLH1 (PSMA)*	177Lu-PSMA-617	Prostate (32% ORR)

FIG. 8